NOT-HG-21-016: Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21)

Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21)

Notice Number:

NOT-HG-21-016

Key Dates

Release Date:

December 02, 2020

Estimated Publication Date of Funding Opportunity Announcement:

February 01, 2021

First Estimated Application Due Date:

June 25, 2021

Earliest Estimated Award Date:

May 02, 2022

Earliest Estimated Start Date:

May 02, 2022

Related Announcements

NOT-HG-21-017 - Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)

NOT-HG-21-019 - Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial Not Allowed)

Issued by

National Human Genome Research Institute (NHGRI)

Purpose

The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R21 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development:

The purpose of the RFA is to refocus and emphasize NHGRI’s investment in nucleic acid sequencing technology on novel technology innovation and early development.

This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects.

The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.

Details of the planned FOA are provided below.

Research Initiative Details

The goal is to develop transformative new technologies to dramatically advance DNA sequencing and direct RNA sequencing with the anticipation of making major contributions to the NHGRI mission and the field of genomics. Applications will be expected to include transformative proposed research for new nucleic acid sequencing technologies and the early-stage development of related technical advances that have the potential to substantively overcome limitations in current approaches for 1) DNA sequencing and 2) direct sequencing of entire cellular RNA molecules. High-risk/high-payoff applications will be appropriate to achieve the goals of this FOA.

Funding Information

Estimated Total Funding

TBD

Expected Number of Awards

TBD

Estimated Award Ceiling

TBD

Primary CFDA Numbers

93.172

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Michael W. Smith, Ph.D.
National Human Genome Research Institute (NHGRI)
301-480-3413
[email protected]